The Th1/Th2 paradigm and the allograft response

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 688-693

  Strom, Terry B ^a   Roy Chaudhury, Prabir ^a   Manfro, Roberto ^a   Xheng, Xin Xiao ^a   Nickerson, Peter W ^a   Wood, Kathryn ^b   Bushell, Andrew ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; SHORT SURVEY; T LYMPHOCYTE;

EID: 0030272486     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80087-2     Document Type: Article

References (38)

1. O'Connell PJ, Pacheco-Silva A, Nickerson PW, Muggia RA, Bastos M, Kelley VR, Strom TB. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol. 150:1993;1093-1104.
2. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation. 53:1992;1281-1294.
3. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med. 174:1991;493-496.
4. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med. 173:1991;79-87.
5. Nickerson P, Pacheco-Silva A, O'Connell PJ, Steurer W, Kelley VR, Strom TB. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction. Transplant Proc. 25:1993;984-985.
6. Bugeon L, Cuturi MC, Hallet MM, Paineau J, Chabannes D, Soulillou JP. Peripheral tolerance of an allograft in adult rats - characterization by low interleukin-2 and interferon-gamma mRNa levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation. 54:1992;219-225.
7. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 181:1995;1869-1874.
8. Binder J, Lehmann M, Graser E, Hancock WW, Watschinger B, Onodera K, Sayegh MH, Volk Hd, Kupiec-Weglinski JW. The effects of non-depleting CD4 targeted therapy in presensitized rat recipients of cardiac allografs. Tranplantation. 61:1996;804-811.
9. Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of Il-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation. 59:1995;559-565.
10. Hancock WW, Sayegh MH, Kwok Ca, Weiner HL, Carpenter CB. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation. 55:1993;1112-1118.
11. Lowry RP, Takeuchi T. the Th1, Th2 Paradigm and Transplantation Tolerance in Medical Intelligence Unit. 1994;RG Landes Company, Austin, Texas.
12. Kupiec-Weglinski Jw, Wasowska B, Papp I, Schmidbauer G, Sayegh MH, Baldwin WM III, Wieder KJ, Hancock WW. CD4 mAb theraphy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol. 151:1993;5053-5061.
13. + T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation. 59:1995;1155-1161.
14. Larsen CP, Elwood Et, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burdern C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, et al. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathway. Nature. 381:1996;434-438.
15. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J immunol. 155:1995;489-498.
16. Chazen GD, Pereira GM, LeGros G, Gillis S, Shevach EM. Interleukin-7 is a T-cell growth factor. Proc Natl Acad Sci USA. 86:1989;5923-5927.
17. Burton Jd, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann Ta. A lymphokine, provisionally designated interleukin T and produced by a human adult t-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. 91:1994;4935-4939.
18. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, fung V, Beers C, Richardson J, Schoenbom MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:1994;965-968.
19. Tagaya Y, Bamford RN, DeFillippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signalling pathways whose expression is controlled at multiple levels. Immunity. 4:1996;329-336.
20. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 154:1995;483-490.
21. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation. 1996;. in press.
22. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, DeBose R, Cosman D, Park LS, Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the Il-2 receptor. EMBO J. 14:1995;3654-3663.
23. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:1994;2822-2830.
24. Mathews DJ, clark Pa, Herbert J, Morgan G, Armitage RJ, Kinnon c, Minty A, Grabstein KH, Caput D, Ferrara P, Callard R. Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of x-linked severe combined immunodeficient B cells to IL-2, IL-4, Il-13, and IL-15. Blood. 85:1995;38-42.
25. Leonard WJ, Noguchi M, Russell SM. Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for x-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol. 365:1994;225-232.
26. Sugamora K, Asao H, Kondo M, Tanaka N, Ishii N, Nakamura M, Takeshita T. The common gamma-chain for multiple cytokine receptors. Adv Immunol. 59:1996;225-275.
27. Johnson JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, Pierce JH, O'Shea JJ. Interleukins 2, 4, 7 and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J Biol Chem. 270:1995;28527-28530.
28. Johnson JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Grupta S, Chen QY, Giri JD, O'Shea JJ. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA. 92:1995;8705-8709.
29. of outstanding interest Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity. 2:1995;331-339 This paper explores cytokine redundancy and pleiotropism at the level of signal transduction and identifies common STAT proteins that are involved in the signal transduction pathways of different cytokines.
30. Leonard WJ, Noguchi M, Russell SM, McBridge OW. The molecular basis of x-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. J Immunol. 138:1995;61-86.
31. of special interest Konieczny BT, Saleen S, Lowry RP, Lakkis Fg. Vigorous cardiac allograft rejection in IFN gamma gene knockout mice [abstract]. Proceedings 15th Annual Meeting of the American Society of Transplant Physicans: 1996 May. 1996;170 Slack Publishers, Throfare, New Jersey, This abstract demonstrates that mice lacking IFN-γ are able to reject cardiac allografts. These results support those in [15] and indicate that no single cytokine is indispensable in the rejection process. This study once again brings out the tremendous redundancy in the alloimmune response.
32. of special interest Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol. 154:1995;5590-5600 This study demonstrates that a long-acting IL-10 fusion protein (Th2-type cytokine) accelerates islet allograft rejection. These results once again argue against the association of Th1 cytokines with rejection and Th2 cytokines with tolerance.
33. Li W, Lu Y, Li Y, Fu JJ, Fung SK, Narula SK, Thompson AW, Zian S. Differential effects of IL-10 on cardiac allograft survival. Exacerbation of rejection is associated with enhanced alloantibody and CTL responses [abstract]. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians: 1996 May. 1996;129 Slack Publishers, Throfare, New Jersey.
34. of special interest Nickerson P, Zheng XX, Steiger J, Steele AW, Steurer W, Roy-Chaudhury P, Muller W, Strom TB. Prolonged islet allograft acceptance in the absence of IL-4 expression. Transplantation. 1996; See annotation [36].
35. of special interest Lakkis FG, Konieczny BT, Lowry RP, Linsley RP, Linsley PS, Alexander Dz, Pearson TL, Larsen CP. Prolonged cardiac allograft survival in IL-4 gene knockout mice treated with CTLA-4-Ig [astract]. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicans: 1996 May. 1996;119 Slack Publishers, Throfare, New Jersey, See annotation [36].
36. of special interest Bushell A, Roy-Chaudhary P, Manfro RC, Zheng XX, Nickerson PW, Li YS, Wood K, Strom TB. IL-4 does not influence the rate of cardiac allograft engraftment: studies in IL-4 knockout mice [abstract]. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicans: 1996 May. 1996;119 Slack Publishers, Throfare, New Jersey, This abstract, along with [34,35], demonstrates that the failure to express IL-4 (IL-4 KO mice) does not obviate the capacity of treatment with CTLA4/Fc fusion proteins or CD4 mAbs to promote long-term engraftment/tolerance in murine islet and cardiac allograft models.
37. Bishop GA, Sun J, DeCruz DJ, Rokahr KL, Sedgewick JD, Shell AGR, Gallagher MD, McCougham GW. Tolerance to rat liver allografts. III. Donor cell migration and tolerance assisted cytokine production in peripheral lymphoid tissues. J Immunol. 156:1996;4925-4931.
38. Flores-Villanueva PO, Zheng XX, Strom TB, Stadecker MJ. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol. 156:1996;3315-3320.